Navigation Links
RSB Spine, LLC, Announces Distribution Agreement with Paradigm BioDevices, Inc.
Date:9/30/2009

CLEVELAND, Sept. 30 /PRNewswire/ -- RSB Spine, LLC, today announced that it has signed an exclusive master distribution agreement with Paradigm BioDevices, Inc. for the U.S. market. Paradigm BioDevices was instrumental in developing the Stand Alone 360 market for ZERO-Profile(SM) ALIF implants, which is one of the fastest growing segments in the spine market. RSB Spine's growing portfolio of modular fusion products offers surgeons more choices than existing technologies in the zero profile segment of the market. Moreover, RSB Spine will introduce two new products this year, and two additional products in 2010, making the need for effective distribution critical to the ongoing success of the company.

RSB Spine Chief Executive Officer John A. Redmond said: "We are delighted with this partnership and believe that Paradigm BioDevices' proven success and expertise in this market will greatly enhance our efforts to bring unique, surgeon-friendly implants to RSB's customers. Distribution is one of the most difficult aspects of this business, and we are confident that Paradigm BioDevices will provide increased opportunities for access to quality agents and rapid sales growth."

Paradigm BioDevices, Inc., Chief Executive Officer Mike O'Neill said: "RSB's product portfolio is a truly innovative and remarkable platform that offers surgeons the ability to select material and mechanical properties that best meet their patients' individual needs. We are excited to be involved with RSB's unique products and the diverse market opportunity they afford."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants with a focus on modular fusion products.

Paradigm BioDevices is a privately held manufacturer and distributor of minimally invasive tissue collection systems and novel spinal implant technologies. The company, founded in 1997, is based in Boston and has a U.S. distribution network of 68 agents and more than 250 representatives.

SOURCE RSB Spine, LLC


'/>"/>
SOURCE RSB Spine, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):